Merrill Keeps 'Strong Buy' on Pfizer

Still, analyst Steven Tighe says he sees very little overlap in the drug giant's plans to buy Pharmacia in a $60 billion deal

Merrill Lynch says Pfizer 's (PFE ) deal to acquire Pharmacia (PHA ) for $60 billion shows "very little overlap."

To continue reading this article you must be a Bloomberg Professional Service Subscriber.